4609 Background: The epidermal growth factor receptor (EGFR) is a potentially important
target in PC. Benefit from erlotinib (Tarceva), an oral EGFR tyrosine kinase inhibitor has …

Background and aim: Previous studies have demonstrated the efficacy and safety of
combining Gemcitabine and Erlotinib (Gem-Erlo) for the treatment of pancreatic cancer …

Background A randomized clinical trial has found that the addition of erlotinib to gemcitabine
(GEM-E) for pancreatic cancer led to a modest increase in survival. The aim of this national …

Background: Prognosis of advanced pancreatic cancer is dismal and the novel targeted
therapies, albeit successfully used to treat many advanced tumors, have shown modest …

Methods Sixty-nine patients with advanced pancreatic cancer who were treated with daily
erlotinib 100 mg orally and gemcitabine 1,000 mg/m 2/30 min intravenous infusion on days …

To date, only limited toxicity data are available for the combination of erlotinib with either
capecitabine or gemcitabine as front-line therapy for advanced pancreatic cancer. Within a …

The concept of extending good 'quality of life'is the cornerstone upon which treatment
options for metastatic pancreatic cancer need to be built, as locally advanced or metastatic …

4611 Background: Erlotinib is an EGFR TKI active in combination with gemcitabine in p with
advanced pancreatic cancer (PC). The combination of gemcitabine and bevacizumab is also …

Objectives Several clinical trials have been published on gemcitabine-based chemotherapy
with or without addition of agents against epidermal growth factor receptor (EGFR) or …